Capital Fund Management (CFM)
BPMC

Capital Fund Management (CFM)’s Blueprint Medicines BPMC Stock Holding History

Capital Fund Management (CFM)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,500
Closed -$2.11M – 2450
2025
Q2 		$2.11M Sell
16,500
-100
-0.6% -$10.4K 0.01% 1653
2025
Q1 		$1.47M Sell
16,600
-5,300
-24% -$517K ﹤0.01% 1535
2024
Q4 		$1.91M Sell
21,900
-8,000
-27% -$733K ﹤0.01% 1508
2024
Q3 		$2.77M Buy
29,900
+11,400
+62% +$1.13M 0.01% 1281
2024
Q2 		$1.99M Buy
18,500
+7,400
+67% +$741K 0.01% 1383
2024
Q1 		$1.05M Sell
11,100
-3,100
-22% -$266K ﹤0.01% 1691
2023
Q4 		$1.31M Buy
+14,200
New +$920K ﹤0.01% 1731

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capital Fund Management (CFM)'s BPMC Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 11,820 shares — an estimated $1.52M sold.

Capital Fund Management (CFM) first reported a position in BPMC in Q2 2018 and held it in 13 quarters. The position peaked at $8.1M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 11,820 Blueprint Medicines shares in Q3 2025, an estimated $1.52M.
  • Capital Fund Management (CFM) first reported a position in Blueprint Medicines in Q2 2018 and held it in 13 quarters.
  • Capital Fund Management (CFM)'s Blueprint Medicines position peaked at $8.1M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.